Lymphoblastic Cell Lines in Pharmacogenomics: How applicable are they in clinical outcomes?

Lymphoblastoid cell lines (LCLs) are widely used in pharmacogenomic studies and the applicability of LCLs for various clinical phenotypes is emerging. Early studies have yielded promising results for LCLs as a proxy for genetic variants in treatment outcome for a number of cancers, as well as toxicity in varying tissue types including taxane-induced neuropathy. Although LCLs have demonstrated utility in the elucidation of functional mechanisms for results of clinical genotype–drug phenotype studies, there are more relevant cell-based models developing. Utility of LCLs as a resource in pharmacogenomic discovery